Zobrazeno 101 - 110
of 320
pro vyhledávání: '"Anne Floquet"'
Autor:
Stamatios Petousis, Sabrina Croce, Michel Kind, Caroline Lalet, Guillame Babin, Chrysoula Margioula-Siarkou, Dennis Querleu, Anne Floquet, Marina Pulido, Frederic Guyon
Publikováno v:
Trials in progress abstract.
Autor:
Susana Banerjee, Nicoletta Colombo, Antonio González-Martín, Carol Aghajanian, Giovanni Scambia, William H. Bradley, Ana Oaknin, Theresa Cain, Kathleen N. Moore, Elizabeth S. Lowe, Anne Floquet, Amit M. Oza, Alla Lisyanskaya, Alexandra Leary, Paul DiSilvestro, Byoung-Gie Kim, Gabe S. Sonke, Charlie Gourley, Michael Friedlander
Publikováno v:
Gynecologic Oncology. 162:S25-S26
Objectives: Newly diagnosed advanced ovarian cancer patients (pts) are at high risk of relapse and 5-year survival is 30–50%. Delay of recurrence, prolonged survival and, for some pts, increased chance of cure are goals of treatment in this setting
Autor:
Elodie Girard, Suzy Scholl, Pierre Gestraud, Els M.J.J. Berns, Virginie Fourchotte, Maud Kamal, Aurélien Latouche, Charlotte Lecerf, Attila Kereszt, Sergio Roman Roman, Balazs Balint, Gemma Kenter, Fabrice Lecuru, Anne Floquet, Anne de la Rochefordiere, Marina Popovic, Heiko von der Leyen, Roman Rouzier, Leanne de Koning, Jonas Béal, Vincent Puard, Charlotte Ngo
Publikováno v:
EBioMedicine, 61:103049. Elsevier
Scholl, S M, Beal, J, de Koning, L, Girard, E, Popovic, M, de la Rochefordière, A, Lecuru, F, Fourchotte, V, Ngo, C, Floquet, A, Berns, E MJJ, Kenter, G, Gestraud, P, von der Leyen, H, Lecerf, C, Puard, V, Roman, S R, Latouche, A, Kereszt, A, Balint, B, Rouzier, R & Kamal, M 2020, ' Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer ', EBioMedicine, vol. 61, 103049 . https://doi.org/10.1016/j.ebiom.2020.103049
EBioMedicine
EBioMedicine, Elsevier, 2020, 61, pp.103049-. ⟨10.1016/j.ebiom.2020.103049⟩
EBioMedicine, 61:103049. Elsevier BV
EBioMedicine, Vol 61, Iss, Pp 103049-(2020)
Scholl, S M, Beal, J, de Koning, L, Girard, E, Popovic, M, de la Rochefordière, A, Lecuru, F, Fourchotte, V, Ngo, C, Floquet, A, Berns, E MJJ, Kenter, G, Gestraud, P, von der Leyen, H, Lecerf, C, Puard, V, Roman, S R, Latouche, A, Kereszt, A, Balint, B, Rouzier, R & Kamal, M 2020, ' Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer ', EBioMedicine, vol. 61, 103049 . https://doi.org/10.1016/j.ebiom.2020.103049
EBioMedicine
EBioMedicine, Elsevier, 2020, 61, pp.103049-. ⟨10.1016/j.ebiom.2020.103049⟩
EBioMedicine, 61:103049. Elsevier BV
EBioMedicine, Vol 61, Iss, Pp 103049-(2020)
BACKGROUND Cervical cancer (CC) remains a leading cause of gynaecological cancer-related mortality world wide and constitutes the third most common malignancy in women. The RAIDs consortium ( http://www.raids-fp7.eu/ ) conducted a prospective Europea
Autor:
Pauline Wimberger, Anne Floquet, Michel Fabbro, Marina Popovic, Suzy Scholl, Goran Malenkovic, Noreen Gleeson, Jean-Marc Classe, Elodie Girard, Eleonor Rivin del Campo, Delphine Garbay, Mathieu Minsat, Sylvain Dureau, Katarina Koprivsek, Peter Hillemanns, Eric Deutsch, Nicolas Servant, Maud Kamal, Coraline Dubot, Ekaterina S. Jordanova, Heiko von der Leyen, Charlotte Ngo, Leanne de Koning, Branislav Djuran, Sorin Dema, Marius Craina, Anne de la Rochefordiere, Aljosa Mandic, Charles Coutant, Jean Guillaume Feron, Madalin Margan, Nina Samet, Els M.J.J. Berns, Sanne Samuels, István Nagy, Philippe Morice, Pierre Emmanuel Colombo, Roman Rouzier, Balázs Bálint, Henry Zijlmans, Philippe Hupé, Frédéric Marchal, Gemma G. Kenter, Alis Dema, Nathalie Mesgouez-Nebout, Pierre Gestraud, Fabrice Lecuru, Virginie Fourchotte, Attila Kereszt, Frédéric Guyon, Nicolas de Saint-Jorre, Alexia Savignoni, Pierre Fumoleau, Christine Kerr
Publikováno v:
EBioMedicine
EBioMedicine, Vol 57, Iss, Pp 102875-(2020)
EBioMedicine, Vol 57, Iss, Pp 102875-(2020)
BACKGROUND: There is a lack of information as to which molecular processes, present at diagnosis, favor tumour escape from standard-of-care treatments in cervical cancer (CC). RAIDs consortium (www.raids-fp7.eu), conducted a prospectively monitored t
Autor:
C. Pomel, Claire Labreveux, E. Barranger, Magali Provansal, A.M. Savoye, Florence Joly, Roman Rouzier, J-M Classe, Patricia Pautier, Laurence Gladieff, T. de La Motte Rouge, Pierre Meeus, C. Guillemet, Frédéric Marchal, S Causeret, Thierry Petit, Eric Leblanc, Anne Floquet, C Romeo, Loïc Campion, Manuel Rodrigues, I.L. Ray-Coquard, S Gourgou, C. Courtinard
Publikováno v:
ePoster.
Introduction/Background In SOLO1 trial, maintenance therapy with olaparib considerably improved progression-free survival (PFS) among women with newly-diagnosed, advanced BRCA-mutated HGEOC. Based on the large real-life ESME ovarian cancer (OC) cohor
Autor:
J-M Classe, Fabrice Lecuru, C. Pomel, Elsa Kalbacher, Nina Radosevic-Robin, Sebastien Gouy, Nicolas Chopin, M Angeles-Fite, T. de La Motte Rouge, Dominique Berton-Rigaud, H Bonsang Kitzis, C. Lefeuvre-Plesse, Patricia Pautier, F Guyon, Magali Provansal, Anne Floquet, C. Lenck, R. Ramanah, Eric Leblanc, Frédéric Selle, E Lambaudies, Isabelle Treilleux, S. Martin, Frédéric Beurrier, P Meus, I.L. Ray-Coquard, A. Lesoin, Florence Joly, C Martinez Gomez
Publikováno v:
ePoster Talks: Ovarian + Endometria.
Introduction/Background Surgery is the cornerstone of ovarian Granulosa Cell Tumor (GCT). Complete resection with adequate staging is the gold standard in 1st line setting. The aim of this study is to assess the impact of an appropriate surgery accor
Autor:
Nicoletta Colombo, Antonio González-Martín, B Schmalfeldt, I.L. Ray-Coquard, J. Maenpaa, Keiichi Fujiwara, E.M. Guerra Alia, Michel Fabbro, IB Runnebaum, P. Harter, C Cropet, Ahmed El-Balat, Eric Pujade-Lauraine, Sandro Pignata, G. Bogner, AC Hardy Blessard, Domenica Lorusso, Marie-Ange Mouret-Reynier, Anne Floquet, Ignace Vergote
Publikováno v:
Best Oral Communications/Late-Breaking Abstracts 3 – Ovarian Cancer.
Introduction/Background In the Phase III SOLO1 first-line trial, maintenance therapy with the PARP inhibitor olaparib provided a substantial progression-free survival (PFS) benefit to advanced ovarian cancer (OC) patients who have a BRCA1/2 mutation
Autor:
Alla Lisyanskaya, Nicoletta Colombo, Giovanni Scambia, Charlie Gourley, Gabe S. Sonke, William H. Bradley, Anne Floquet, Alexandra Leary, Ralph Bloomfield, Kathleen N. Moore, B-G Kim, Amit M. Oza, Elizabeth S. Lowe, P. DiSilvestro, Antonio González-Martín, Cara Mathews, Ana Oaknin, Susana Banerjee, Michael Friedlander, Carol Aghajanian, Joyce F. Liu
Publikováno v:
Oral Communication 1 – Gynaecological Cancer.
Introduction/Background In SOLO1 (NCT01844986; GOG-3004), maintenance olaparib significantly improved progression-free survival (PFS) vs placebo (HR 0.30; 95% CI 0.23–0.41; P Methodology SOLO1 recruited patients who had undergone upfront or interva
Autor:
Carine Valle, Gaëtan MacGrogan, Loubna Mhamdi, Noémie Thébault, Sabrina Croce, Laetitia Mayeur, Frédéric Guyon, Flora Rebier, Tom Lesluyes, Isabelle Soubeyran, Jean-Christophe Noel, Camille Chakiba, Gaëlle Pérot, Denis Querleu, Anne Floquet, Sophie Le Guellec, Mojgan Devouassoux-Shisheboran, Eberhard Stoeckle, Frédéric Chibon, Quitterie Fontanges
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(4)
Purpose: Uterine leiomyosarcoma, which accounts for 7% of all soft-tissue sarcomas and 1%–3% of all uterine malignancies, is an aggressive tumor responsible for a significant proportion of uterine cancer–related deaths. While Federation Internati
Autor:
Gilles Freyer, Jean Emmanuel Kurtz, Guelten Oskay-Oezcelik, Raymond Despax, Michel Fabbro, Dominique Berton-Rigaud, Elsa Kalbacher, Idlir Licaj, Marie Christine Kaminsky-Forrett, N. Dohollou, Alain Lortholary, Jalid Sehouli, Anne Floquet, Florence Joly Lobbedez, Nicolas Gane, Rémy Largillier, Marianne Lorcet, Pierre Combe, Isabelle Ray-Coquard, Thibault De La Motte Rouge, Anne Claire Hardy Bessard
Publikováno v:
Bulletin du Cancer. 105:465-474
Resume Introduction Expression IV est une enquete europeenne evaluant les attentes des patientes suivies pour un cancer de l’ovaire concernant les traitements d’entretien. Methode Quatre cent une patientes francaises ont repondu a un questionnair